Advertisement

Search Results

Advertisement



Your search for all items matches 33422 pages

Showing 51 - 100


multiple myeloma

Relapsed or Refractory Multiple Myeloma: Activity of BCMA x CD3 Bispecific Antibody

As reported in the Journal of Clinical Oncology by Bumma et al, the phase II portion of a first-in-human phase I/II trial (LINKER-MM1) showed strong activity with the B-cell maturation antigen (BCMA) x CD3 bispecific antibody linvoseltamab in patients with relapsed or refractory multiple myeloma....

prostate cancer
issues in oncology

PSA May Be Insufficient to Detect Early Prostate Cancer in Transgender Women

Transgender women receiving hormone therapy may skew artificially low on prostate cancer screening tests, thereby providing false reassurance and potentially delaying diagnosis and treatment, according to a recent study published by Nik-Ahd et al in JAMA. The findings indicated that transgender...

survivorship
issues in oncology

Impact of Cisplatin-Based Chemotherapy on Hearing in Cancer Survivors

Researchers have uncovered the long-term effects of cisplatin-based chemotherapy on the hearing of cancer survivors, according to a recent study published by Sanchez et al in JAMA Oncology. Background Cisplatin is commonly used in chemotherapy to treat a variety of cancer types, including...

kidney cancer

Perioperative Nivolumab in Renal Cell Carcinoma

As reported in The Lancet Oncology by Allaf et al, a planned interim analysis of the phase III PROSPER ECOG-ACRIN EA8143 trial showed no recurrence-free survival benefit with perioperative nivolumab vs observation in patients undergoing nephrectomy for high-risk renal cell carcinoma.  Study ...

breast cancer
supportive care
symptom management
integrative oncology

Tai Chi vs Cognitive Behavioral Therapy: Measuring Inflammatory Biomarkers in Breast Cancer Survivors With Insomnia

Both tai chi and cognitive behavioral therapy may reduce insomnia and inflammation and bolster antiviral defenses in breast cancer survivors, according to a recent study published by Irwin et al in Brain, Behavior, and Immunity.   Background Chronic insomnia—one of the most prominent symptoms...

solid tumors
issues in oncology

New Study Demonstrates Similar Outcomes Between Patients With Protocol Exceptions to Participate in Targeted Therapy Trial and Eligible Participants

Patients with treatment-refractory tumors who received eligibility and testing waivers to participate in a large basket/umbrella oncology trial demonstrated similar rates of clinical benefit and adverse events compared with patients who participated in the trial without waivers, according to recent ...

gastroesophageal cancer

In Gastroesophageal Cancer, ‘Switch’ Maintenance Improves Outcomes Over Chemotherapy Continuation

In patients with advanced HER2-negative gastric or gastroesophageal junction cancer and disease control after oxaliplatin-based chemotherapy, “switch” maintenance with paclitaxel plus ramucirumab in the phase III ARMANI trial significantly improved both progression-free and overall survival,...

health-care policy

ASCO: SCOTUS Ruling Upends Country’s Regulatory Framework, Threatens to Complicate and Delay Health-Care Delivery

The Association for Clinical Oncology (ASCO) has serious concerns about the impact of the Supreme Court’s rulings in Loper Bright Enterprises v Raimondo and Relentless, Inc. v Department of Commerce on cancer care. These decisions overturned the “Chevron deference” or “Chevron doctrine,” a legal...

ASCO, Friends of Cancer Research Applaud FDA Draft Guidance

The Association for Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) are applauding efforts by the U.S. Food and Drug Administration (FDA) to broaden eligibility criteria for cancer clinical trials in order to include more diverse patient populations. In joint comments submitted on ...

ASCO to Present Ethan Basch, MD, MSc, FASCO, With the Joseph Simone Quality Care Award

ASCO will recognize Ethan Basch, MD, MSc, FASCO, a medical oncologist and Distinguished Professor at the University of North Carolina, with the Joseph Simone Quality Care Award and Lecture at the 2024 ASCO Quality Care Symposium.  This year’s meeting will be held in San Francisco and online on...

breast cancer

Primary Breast Cancer: Pretreatment Exercise Level and Distant Recurrence–Free Interval

In a French study (CANTO) reported in the Journal of Clinical Oncology, Soldato et al found that increasing pretreatment exercise levels was associated with a longer distant recurrence–free interval up to a threshold exercise level in patients with primary breast cancer. The benefit of exercise...

multiple myeloma

Transplant-Eligible Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the CASSIOPEIA Trial

As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, long-term follow-up of the phase III CASSIOPEIA trial has shown improved progression-free survival with daratumumab maintenance vs observation both among newly diagnosed patients with transplant-eligible multiple myeloma who ...

lung cancer

Second-Line Therapy With Adagrasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer

Second-line therapy with the KRAS inhibitor adagrasib modestly improved progression-free survival and objective response rate over docetaxel in previously treated patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to the primary analysis of the phase III...

hepatobiliary cancer
gastroesophageal cancer
colorectal cancer
issues in oncology
supportive care

Strategies for Reducing the Risk of Cancers in Patients With Alcohol Dependence

Investigators have uncovered the potential benefit of undergoing alcohol rehabilitation and maintaining abstinence in patients with alcohol dependence at risk of developing alcohol-associated cancers, according to a recent study published by Schwarzinger et al in The Lancet Public Health. The...

skin cancer
issues in oncology

Novel Spatial Gene-Signature Approach May Help to Predict Immunotherapy Outcomes in Patients With Melanoma

Researchers have demonstrated that spatial gene signatures may enhance the prediction of immunotherapy outcomes in patients with melanoma, according to a recent study published by Aung et al in Clinical Cancer Research. The current gene signatures used to predict immunotherapy outcomes may lack...

breast cancer

Milana Bergamino Sirvén, MD, PhD, on HER2-Positive Early-Stage Breast Cancer: Molecular Profiling, Prognosis, and Treatment Options

Milana Bergamino Sirvén, MD, PhD, of Spain’s Institute of Cancer Research, discusses her findings on molecular profiling of patients with estrogen receptor–positive, HER2-positive early-stage breast tumors after short-term preoperative endocrine therapy. This study suggests that such profiling may...

breast cancer

Ciara C. O’Sullivan, MD, MBBCh, on HER2-Positive Breast Cancer: Expert Commentary on Treatments Under Study

Ciara C. O’Sullivan, MD, MBBCh, of Mayo Clinic, discusses three studies of treatment for patients with HER2-positive metastatic breast cancer and their clinical implications: the EMERALD trial of eribulin and taxane; the Patricia Cohort C trial of palbociclib plus trastuzumab and endocrine therapy; ...

colorectal cancer

Neoadjuvant Combination of PD-1 and Angiogenesis Inhibitors in Genomically Unstable Colorectal Cancer: NEOCAP

As reported in The Lancet Oncology by Yu et al, based on results from the ongoing phase II NEOCAP trial, neoadjuvant therapy with the PD-1 inhibitor camrelizumab plus the angiogenesis inhibitor apatinib appears to demonstrate “promising” antitumor activity and a manageable toxicity profile in...

colorectal cancer

Adding COX-2 Inhibition to Chemotherapy in PIK3CA-Activated Stage III Colon Cancer

In an analysis from the CALGB/SWOG 80702 (Alliance) trial published by Nowak et al in the Journal of Clinical Oncology, researchers found that the addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant chemotherapy was associated with improved disease-free survival and...

lymphoma

FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma

On June 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy. EPCORE ...

breast cancer
issues in oncology

Can Chemotherapy Impact the Gut Microbiome in Patients With Breast Cancer?

Researchers have uncovered the impact of chemotherapy on the gut microbiome in patients with breast cancer, according to a recent study published by Otto-Dobos et al in Brain, Behavior, and Immunity. Background Chemotherapy is known to cause behavioral side effects, including cognitive decline....

kidney cancer
issues in oncology

Novel Biomarker May Be Predictive of Clear Cell Renal Cell Carcinoma Recurrence

Researchers have discovered a biomarker that could help identify which patients with clear cell renal cell carcinoma may be at greater risk of cancer recurrence, according to a recent study published by Mehra et al in JCO Precision Oncology. Background Approximately 3% to 5% of all cancer diagnoses ...

breast cancer

Phase III postMONARCH Trial: Switching to Abemaciclib May Improve Outcomes After Disease Progression

For hormone receptor–positive, HER2-negative advanced breast cancer that has progressed on CDK4/6 inhibition plus endocrine therapy, the CDK4/6 inhibitor abemaciclib plus fulvestrant significantly reduced the risk of further disease progression in the phase III postMONARCH study.1 “The postMONARCH ...

head and neck cancer

Recurrent or Metastatic HNSCC: First-Line VEGFR2 Plus PD-1 Inhibition

In a single-center phase I/II trial reported in The Lancet Oncology, Douglas Adkins, MD, and colleagues found that the recommended phase II dose of ramucirumab combined with pembrolizumab was active in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell...

breast cancer

ER-Positive Advanced Breast Cancer: Oral SERD Plus Palbociclib in First-Line Setting

As reported in the Journal of Clinical Oncology by Javier Cortés, MD, PhD, and colleagues, the phase III AMEERA-5 trial of first-line treatment with the selective estrogen receptor degrader (SERD) amcenestrant plus palbociclib vs letrozole plus palbociclib in estrogen receptor (ER)-positive,...

issues in oncology

New Survey Finds Cancer Drug Shortage Management Remains a Moving Target

The National Comprehensive Cancer Network® (NCCN®) published new results from its latest survey on cancer drug shortages in the United States. This follows data published 1 year ago and 6 months ago illustrating how up to 93% of centers surveyed were experiencing shortages of the crucial...

breast cancer
supportive care
symptom management

Can Acupuncture Improve Hormonal Side Effects in Women Undergoing Breast Cancer Therapy?

Acupuncture may be effective at reducing the hormonal side effects of endocrine therapy in women with breast cancer, according to a recent study published by Lu et al in Cancer.   Background Although endocrine therapy—which is capable of blocking the hormone signaling that drive some types of...

solid tumors
issues in oncology
genomics/genetics

Early Surveillance in Pediatric Patients Genetically Predisposed to Cancer

Initiating surveillance soon after recognizing a pediatric patient has a genetic predisposition for cancer may improve the identification of early-stage asymptomatic tumors, according to a recent study published by Blake et al in JAMA Oncology. The findings may inform clinical practice following...

gynecologic cancers

Estrogen Alone Increased Ovarian Cancer Incidence and Mortality, Combination Hormone Therapy Did Not

In 2002, the federally funded Women’s Health Initiative (WHI),1 a randomized, placebo-controlled clinical trial investigating menopausal hormone therapy for healthy menopausal women, was abruptly halted when it was determined that taking estrogen and progestin hormones after menopause increased the ...

ASCO Sets Six Guiding Principles for AI in Oncology

ASCO has released “Principles for the Responsible Use of Artificial Intelligence in Oncology,” to guide the Society’s consideration of all aspects of artificial intelligence (AI). With this manuscript, ASCO joins colleagues across medicine in offering principles that should be applied in...

supportive care

ASCO Issues New Guidance on Cannabis and Cannabinoid Use in Adults With Cancer

Many Americans, including patients with cancer, use cannabis and cannabinoids. In response to this reality, ASCO has issued a guideline for clinicians, adults with cancer, caregivers, and researchers on their medical use.1 The recommendations cover all cancer types and address products ranging from ...

breast cancer
survivorship

Long-Term Study Finds Most Breast Cancer Survivors Were Able to Preserve Fertility and Achieve Pregnancy After Diagnosis

Research examining fertility and attempts at pregnancy among young women after a breast cancer diagnosis has been hampered by short-term follow-up and a lack of prospective assessment of pregnancy attempts. However, a long-term study investigating fertility outcomes among young women who reported...

gynecologic cancers

Retroperitoneal Lymphadenectomy: Can It Be Safely Omitted for Some Patients With Advanced Ovarian Cancer?

Adding retroperitoneal lymphadenectomy to cytoreductive surgery during primary debulking surgery or interval cytoreductive surgery after neoadjuvant chemotherapy failed to improve progression-free or overall survival in patients with advanced ovarian cancer who have no suspicious nodes, according...

gynecologic cancers

Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

On March 22, 2024, mirvetuximab soravtansine-gynx (Elahere) was granted regular approval for adult patients with folate receptor–alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment...

cns cancers

Tovorafenib in Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

On April 23, 2024, tovorafenib (Ojemda) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for patients aged 6 months and older who have relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation.1 Tovorafenib is a...

multiple myeloma

DREAMM-8: Belantamab Mafodotin-blmf Shows ‘Robust’ Benefit in Early Relapse of Myeloma

Recent phase III findings support the antibody-drug conjugate belantamab mafodotin-blmf as a treatment option for patients with multiple myeloma in early relapse. Belantamab mafodotin is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) expressed on multiple myeloma cells,...

lung cancer
palliative care

Advanced Lung Cancer: Studies Explore Palliative Care Delivered by Telehealth and in a Stepped-Care Approach

Early palliative care can be integrated into the course of treatment for patients with advanced lung cancer via delivery by telehealth with outcomes similar to when palliative care is delivered via in-person visits, according to results of the REACH PC trial presented by Joseph Greer, PhD, of...

skin cancer

Accelerating Progress in Melanoma and Cancer Research

The Melanoma Research Alliance is on a mission to cure and prevent melanoma, a skin cancer that is diagnosed in more than 100,000 people each year and is expected to take the lives of more than 8,000 individuals in 2024.1 We invite stakeholders across all fields, including medicine, science, and...

lung cancer

Durvalumab Consolidation Therapy Extends Survival in Limited-Stage Small Cell Lung Cancer

Consolidation therapy with the PD-L1 antibody durvalumab after chemoradiotherapy extended survival in patients with limited-stage small cell lung cancer (SCLC) compared with standard-of-care chemoradiotherapy alone, according to the first planned interim analysis of the phase III ADRIATIC trial...

CSHL and Northwell Health Extend Strategic Affiliation

Leaders from two New York bioscience and health-care institutions came together at Carnegie Hall to acknowledge the signing of an update to their affiliation agreement initiated in 2015. The Cold Spring Harbor Laboratory (CSHL)-Northwell Health agreement ensures continued collaboration and support...

Lu-177 Dotatate for Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors

On April 23, 2024, lutetium Lu-177 dotatate (Lutathera) was approved for pediatric patients 12 years and older with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.1 Lu-177 dotatate is a radiolabeled...

breast cancer

Addition of Adjuvant Ribociclib to Nonsteroidal Aromatase Inhibitor Therapy Improves Survival in Early Breast Cancer

As reported in The New England Journal of Medicine by Dennis Slamon, MD, PhD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues, interim analysis of the phase III NATALEE trial has shown improved invasive disease–free survival with the addition of...

issues in oncology

Study Finds Fewer Than Half of Accelerated Approval Drugs Show Benefit in Overall Survival or Quality of Life Within 5 Years

In 1992, the U.S. Food and Drug Administration (FDA) instituted the Accelerated Approval regulations, which allow drugs that treat serious conditions, including cancer, and fill an unmet need to be approved early based on a surrogate endpoint.1 However, any drug approved under this pathway is still ...

skin cancer

Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma

As reported at the 2024 ASCO Annual Meeting (Abstract 9500) and in The New England Journal of Medicine by Georgina V. Long, MD, PhD, and colleagues, the final, 8-year follow-up analysis of the phase III COMBI-AD trial has shown continued improvements in relapse-free and distant metastasis–free...

lymphoma

Combination Targeted Therapy Produces Durable Responses in Patients With Relapsed DLBCL

The results from a phase Ib/II study of a five-drug regimen of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) show the treatment produced durable remissions in patients with specific molecular...

gastroesophageal cancer
immunotherapy

Pembrolizumab/Chemotherapy in First-Line Treatment of HER2-Negative Advanced Gastric or GEJ Adenocarcinoma

On November 16, 2023, pembrolizumab (Keytruda) was approved with fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.1 Supporting Efficacy Data Approval ...

ASTRO Names New Chief Executive Officer

The American Society for Radiation Oncology (ASTRO) announced that following a nationwide search, Vivek S. Kavadi, MD, MBA, FASTRO, will become Chief Executive Officer of the Society, effective November 1, 2024. Dr. Kavadi will succeed Laura Thevenot, who had already announced her intent to retire...

cns cancers

Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma

On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.1 This represents the first...

lung cancer

Adjuvant Use of Alectinib in ALK-Positive NSCLC

On April 18, 2024, the ALK inhibitor alectinib was approved by the U.S. Food and Drug Administration (FDA) for adjuvant treatment after tumor resection in patients with ALK-positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test.1 Supporting Efficacy Data Approval was based ...

leukemia
lymphoma
issues in oncology

Immunoglobulin G Testing May Reduce Infections, Increase Receipt of Immunoglobulin Replacement Therapy in Patients With CLL and NHL

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) who undergo frequent immunoglobulin G testing may be less likely to experience severe infections than those who don’t undergo frequent testing, according to a recent study published by Soumerai et al in Blood Advances....

Advertisement

Advertisement




Advertisement